Literature DB >> 12757180

Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.

Antoni Stadnicki1, Urszula Mazurek, Maciej Gonciarz, Danuta Plewka, Grazyna Nowaczyk, Joanna Orchel, Ezbieta Pastucha, Andrzej Plewka, Tadcusz Wilczok, Robert W Colman.   

Abstract

The distribution of tissue kallikrein (TK) and its plasma inhibitor, kallistatin in plasma and intestinal tissue, was studied in patients with active ulcerative colitis (UC) and Crohn's disease (CD). TK was localized to goblet cells and kallistatin to epithelial cells of normal human intestine. Both proteins are visualized in macrophages inside granulomas in CD as well as in plasmocytes in both CD and UC. Intestinal tissue kallikrein (ITK) and kallistatin are significantly decreased in inflamed intestine compared to noninflammatory controls. TK mRNA is significantly decreased in intestinal biopsy samples from active UC patients compared with inactive patients or controls. Immunoreactive TK is present in plasma in very low concentrations in patients and did not differ in normal subjects. Plasma kallistatin was significantly decreased in patients with active disease compared to normal controls. Our data suggest that release of TK during inflammation plays a role in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757180     DOI: 10.1023/a:1022569623350

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Kinin effects on ion transport in monolayers of HCA-7 cells, a line from a human colonic adenocarcinoma.

Authors:  A W Cuthbert; S C Kirkland; L J MacVinish
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

2.  In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein.

Authors:  W Xiong; C Q Tang; G X Zhou; L Chao; J Chao
Journal:  J Lab Clin Med       Date:  1992-05

3.  Identification of a tissue kallikrein in human polymorphonuclear leucocytes.

Authors:  C D Figueroa; A G MacIver; K D Bhoola
Journal:  Br J Haematol       Date:  1989-07       Impact factor: 6.998

4.  The effect of bradykinin on intestinal motility and blood flow.

Authors:  S Fasth; L Hultén
Journal:  Acta Chir Scand       Date:  1973

5.  The kallikrein-kininogen-kinin system in chronic inflammation.

Authors:  R M Burch; J R Connor; C W Tiffany
Journal:  Agents Actions       Date:  1989-06

6.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

7.  Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands.

Authors:  W C Wolf; R A Harley; D Sluce; L Chao; J Chao
Journal:  Histochem Cell Biol       Date:  1998-11       Impact factor: 4.304

8.  Alterations in mucosal content of colonic glycoconjugates in inflammatory bowel disease defined by monoclonal antibodies.

Authors:  D K Podolsky; D A Fournier
Journal:  Gastroenterology       Date:  1988-08       Impact factor: 22.682

9.  Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis.

Authors:  R B Sartor; R A DeLa Cadena; K D Green; A Stadnicki; S W Davis; J H Schwab; A A Adam; P Raymond; R W Colman
Journal:  Gastroenterology       Date:  1996-05       Impact factor: 22.682

10.  Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation.

Authors:  R A DeLa Cadena; K J Laskin; R A Pixley; R B Sartor; J H Schwab; N Back; G S Bedi; R S Fisher; R W Colman
Journal:  Am J Physiol       Date:  1991-02
View more
  1 in total

1.  Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.

Authors:  Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.